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Abstract
Background: Computerized decision support systems (CDSSs) are information technology-based software that
provide health professionals with actionable, patient-specific recommendations or guidelines for disease diagnosis,
treatment, and management at the point-of-care. These messages are intelligently filtered to enhance the health
and clinical care of patients. CDSSs may be integrated with patient electronic health records (EHRs) and
evidence-based knowledge.
Methods/design: We designed a pragmatic randomized controlled trial to evaluate the effectiveness of
patient-specific, evidence-based reminders generated at the point-of-care by a multi-specialty decision support
system on clinical practice and the quality of care. We will include all the patients admitted to the internal
medicine department of one large general hospital. The primary outcome is the rate at which medical problems,
which are detected by the decision support software and reported through the reminders, are resolved (i.e.,
resolution rates). Secondary outcomes are resolution rates for reminders specific to venous thromboembolism (VTE)
prevention, in-hospital all causes and VTE-related mortality, and the length of hospital stay during the study period.
Discussion: The adoption of CDSSs is likely to increase across healthcare systems due to growing concerns about
the quality of medical care and discrepancy between real and ideal practice, continuous demands for a meaningful
use of health information technology, and the increasing use of and familiarity with advanced technology among
new generations of physicians. The results of our study will contribute to the current understanding of the
effectiveness of CDSSs in primary care and hospital settings, thereby informing future research and healthcare
policy questions related to the feasibility and value of CDSS use in healthcare systems. This trial is seconded by a
specialty trial randomizing patients in an oncology setting (ONCO-CODES).
Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02577198?term=NCT02577198&rank=1
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Background
Background and rationale
Despite the proliferation of clinical guidelines and con-
tinued efforts by local and national healthcare systems
to optimize decision-making on patient diagnosis, treat-
ment, and management, the quality of medical care is
variable and often suboptimal [1]. There remains an ap-
parent discrepancy between the growing availability of
scientific evidence and the application of this evidence
into medical care [2, 3]. Non-adherence to evidence-
based guidelines, medical errors, and omissions in every-
day practice may occur because of time pressure, inex-
perience, reliance on memory, multitasking, and failures
in healthcare team coordination.
Computerized decision support systems (CDSSs) are
information technology-based software that provide
health professionals with actionable, patient-specific rec-
ommendations or guidelines for clinical care at the
point-of-care; these messages are intelligently filtered
and presented at appropriate times during the decision-
making process in order to enhance patients’ health [4,
5]. The opportunity to improve patient care by increas-
ing clinicians’ accessibility to medical knowledge at the
site of practice represents one of the main incentives for
investing in the development and evaluation of these so-
phisticated information systems.
In particular, studies focusing on the effectiveness of
“new generation” CDSSs demonstrate their potential to
assist with problems raised in clinical practice, decrease
the rate of medication errors, increase clinicians’ adher-
ence to guideline- or protocol-based care, and, ultim-
ately, improve the overall efficiency and quality of
healthcare delivery systems [6–19]. These innovative sys-
tems can be integrated into hospital electronic health re-
cords (EHRs) and feature authoritative point-of-care
information services and evidence-based knowledge [20].
This has led to some early work: a systematic review
assessing the effectiveness of such new generation
CDSSs demonstrated encouraging results [21]. Although
this review did not show CDSSs to affect mortality, they
were shown to moderately improve morbidity outcomes.
Differences were further observed for costs and health
services utilization, but these were often inconsistent in
the direction of effect and small in magnitude. The con-
clusion of a landmark paper, published nearly 15 years
ago, still reflects the current scenario: “Although the
promise of clinical decision support system-facilitated
evidence-based medicine is strong, substantial work re-
mains to be done to realize the potential benefits” [22].
Current research on CDSSs suffers two noteworthy
limitations [5]. First, while numerous studies have evalu-
ated the effectiveness of CDSSs, comparatively few im-
plemented a randomized controlled trial (RCT) design.
Second, most published evaluations of the impact of
CDSSs on healthcare quality were conducted in aca-
demic medical centers using “homegrown” systems that
featured restricted clinical content for particular condi-
tions (e.g., thromboprophylaxis). There is limited re-
search on “mature” CDSSs that are commercially
available and capable of supporting a wide range of clin-
ical activities. Across countries, the adoption of these
systems by hospitals is likely to increase in the future.
Objective
Our study aims to evaluate the effectiveness of patient-
specific, point-of-care reminders generated by the Medil-
ogy Decision Support System (MediDSS) [23] on clinical
practice and the quality of care in a general hospital.
Methods/design
This protocol is reported in accordance with the
SPIRIT 2013 guidance for content of clinical trial
protocols [24, 25].
Trial design
The CODES (computerized decision support) trial will
implement a pragmatic, parallel group and randomized
controlled design with a 1:1 allocation ratio. The flow
diagram of the study can be found in Fig. 1.
Study setting
The study will involve the medical staff of the internal
medicine departments of the Vimercate Hospital from
Azienda Ospedaliera di Desio e Vimercate (AODV) a
multi-site hospital system located in the Lombardy re-
gion of Italy [26]. AODV includes hospitals and health
units distributed in the Province of Monza and Brianza,
Fig. 1 Trial flow chart
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which covers a population of approximately 850,000 in-
habitants. The Vimercate Hospital has a medical staff of
more than 230 doctors, a total of over 900 health profes-
sionals, and an overall capacity of 489 beds. It supports
over 20 specialties and subspecialties. The catchment
population is approximately 200,000 inhabitants, with
more than 15,000 admissions per year. In addition to the
in-patient wards, the hospital houses many facilities for
diagnosis and treatment.
Since 2010, the Vimercate Hospital has been electron-
ically tracking all clinical and administrative information
through an EHR system based on the “Tabula Clinica”
platform (developed by Dedalus S.p.A.) [27].
Eligibility criteria and recruitment
As a pragmatic clinical trial [28, 29], CODES seeks to in-
vestigate the effectiveness of MediDSS reminders in
everyday clinical practice with diverse patients and vary-
ing conditions. Thus, we will enroll all of the patients
admitted into the internal medicine departments of the
AODV, without applying any exclusion criteria.
Intervention
We selected the MediDSS after a comparative assess-
ment of available editorial products using a predefined
set of essential criteria [30, 31]. MediDSS is a product by
Medilogy, an Italian developer of scientific software and
medical technology. Medilogy translated and adapted
Evidence-Based Medicine electronic Decision Support
(EBMeDS) [32], a CDSS developed by Duodecim Med-
ical Publications Ltd., a company owned by the Finnish
Medical Society Duodecim. EBMeDS can be described
as a set of rules (scripts) based on EBM guidelines and
applied to structured health data. MediDSS further in-
cludes knowledge from Swedish, Finnish, Interaction X-
referencing (SFINX), a drug-drug interaction database
containing concise evidence-based information about
the harms and benefits of about 18,000 drug interactions
and adverse events [33].
MediDSS may be used as a stand-alone application, or
may integrate structured patient data from EHR to gen-
erate patient-specific reminders, therapeutic suggestions,
and diagnosis-specific links to full-text guidelines. Re-
minders are automatically generated and displayed on
the monitors of clinicians when they open a patient’s
EHR, enter a new diagnosis, prescribe a drug, or when
new laboratory test results are available. Reminders were
formed using international evidence-based guidelines
and subsequently approved by an international panel of
experts. Our study will use international reminders (n =
262) that cover a large number of health conditions across
specialties and are derived from the EBMeDS and SFINX
database. In addition, 17 local reminders have been care-
fully selected by a team of doctors at Vimercate Hospital,
along with members of the trial team. Table 1 reports
some examples of the reminders. Figures 2 and 3 show a
snapshot of the activation button and of the actual
reminders.
MediDSS reminders will be shown on the EHR of pa-
tients only within the intervention group. During the
care of control group patients, the generated reminders
will not be shown to the physicians, such that the con-
trol is usual clinical practice without the use of the Med-
iDSS service. However, physicians in both groups will
have access to the best evidence for usual care at all
times during the trial through the active searching of
full-text EBM guidelines on the Internet. All participat-
ing physicians will be informed on the availability and
use of the MediDSS system.
Stepped wedge implementation
The intervention is a new technology: its integration in
the current hospital system requires the configuration
and customization of the software. To allow security
controls and successful implementation, the CDSS will
be sequentially rolled out to participants over a number
of time periods. We anticipate that the number of pe-
riods will be limited (i.e., two or three periods). Over an
initial period, all participants will receive the interven-
tion. The order in which participants will receive the
intervention is not determined at random, but will be
determined by selecting physicians prone to provide
constructive feedback to the implementation team. The
RCT adopts a stepped wedge implementation of the
intervention, but not a stepped wedge design [34]. Se-
quential roll-out of the intervention will not be consid-
ered a pilot phase of the trial, but a part of the whole
RCT.
Table 1 Examples of reminders generated by MediDSS from
the EBMeDS and SFINX databases
Clinical reminders in MediDSS
based on EBMeDS database
Drug-drug interaction reminders in
MediDSS based on SFINX database
[66]
Adjusting warfarin dose in atrial
fibrillation: If a patient with atrial
fibrillation and warfarin treatment,
who has not had heart valve
replacement, has not had an INR
test during the last 8 weeks, the
text “Last INR over 8 weeks ago,
order INR?” is shown.
Interaction between spironolactone
and potassium: “The combination
of potassium supplements and
potassium sparing diuretics can
result in hyperkalemia.”
If a new INR result is outside the
range 1.9–3.2, the text “Check
warfarin dose (INR target 2.0–3.0,
but note that if the patient has a
mechanical mitral valve, the INR
target is 2.5–3.5)” is shown, with
link to dose calculator.
Interaction between warfarin and
acetylsalicylic acid: “Concomitant
use is associated with an increased
risk of bleeding.”
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Fig. 2 Screenshot of the CDSS activation button (in red)
Fig. 3 Screenshot of the CDSS activated online remiders
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Selection and development of priority reminders
In order to encourage the participation of the hospital
staff within the study, we invited hospital representatives
to assess the priority needs of the hospital wards and de-
velop a set of reminders to address them. One topic of
particular interest to the hospitals involved venous
thromboembolism (VTE) prevention. The rationale for
the prioritization of this condition is provided below:
(i) Despite evidence supporting the benefits of VTE
prophylaxis based on the risk stratification process
[35] as well as the availability of local hospital
guidelines, the prophylactic drugs were
inconsistently administered among patients.
(ii) The Vimercate Hospital has an increasingly large
population of elderly (aged >65 years) and very elderly
(aged >80 years) subjects, who have a higher risk of
recurrent VTE and acute pulmonary embolism [36].
(iii)Between 2010 and 2012, 45 patients (9.6 %, 95 % CI
7.2–12.6) and 75 patients (16.0 %, 95 % CI 12.9–19.5)
died, respectively, within 30 and 90 days after
discharge due to VTE [36].
(iv)Research has shown the use of CDSSs to improve
the assessment of patients’ risk for VTE, facilitate
appropriate administration of prophylaxis
interventions, and reduce the rate of symptomatic
VTE in hospitalized patients [37–53].
In order to develop the set of reminders for VTE preven-
tion, the local hospital expert group proposed a risk stratifi-
cation process based on the Padua score [54]. This formula
calculates the overall risk (low or high) of VTE for each pa-
tient using both clinical and surgical risk factors. Details of
the underlying algorithm are provided in Table 2.
Besides the VTE prevention therapy reminders, other
scripts were chosen for development and tailored to the
hospital’s needs. The following alerts were identified by
the hospital’s clinicians as of special interest:
– Adjusting warfarin dose in atrial fibrillation
– Alert on heparin-induced thrombocytopenia
– Clopidogrel, prasugrel or ticagrelor, and aspirin in
acute ST-segment elevation myocardial infarction
(STEMI)
– Low-molecular-weight heparin as anticoagulant for
patients with VTE and cancer
– Selection of antithrombotic therapy in atrial
fibrillation on the basis of the CHA2DS2VASc score
– Supplementary laboratory measurements in warfarin
therapy
– Low-dose aspirin: dosing in renal insufficiency
– Drug-drug interaction: aspirin and ACE inhibitor
– Warfarin and paracetamol: drug-drug interaction
– ACE inhibitor or sartan for diabetic patients with
albuminuria
– Glimepiride warning in renal insufficiency
– LDL-cholesterol concentration in patients with type
2 diabetes
– High BNP or proBNP; untreated congestive heart
failure (CHF)?
– Initial laboratory examinations in patients with
congestive heart failure (CHF)
– Beta blockers in the prevention of gastrointestinal
bleeding in patients with cirrhosis
– ACE inhibitors or angiotensin receptor blockers for
patients with diabetes and hypertension but no
microalbuminuria
Qualitative integration
The validity of this RCT relies on the actual implemen-
tation of MediDSS by physicians in their clinical activ-
ities. Healthcare service studies on CDSSs, however,
consistently suggest that the mere provision of such
technology does not guarantee its uptake. In fact, even if
a CDSS is readily available within a hospital, clinicians
often fail to follow its recommendations, ignoring in
some cases up to 96 % of its alerts [55]. Given this con-
text, our RCT is informed by qualitative interviews
aimed to detect the barriers and facilitators to MediDSS
uptake as perceived by diverse health professionals in-
volved in patient care (e.g., physicians and nurses). The
interviews are a part of a larger cross-sectional study,
which involves three Italian hospitals [56]. The inter-
views will explore variables that may hinder the use of a
CDSS in everyday clinical practice, including technical
(e.g., poor usability or knowledge of system), individual
(e.g., negative perception of CDSS or EBM, lack of motiv-
ation), group or organizational (e.g., structural or adminis-
trative constraints), and cultural factors (e.g., adverse
social norms).
Table 2 Description of algorithm for the use of venous
thromboembolism prevention therapy
I. The algorithm incorporates the Padua score [54], which uses ten
common risk factors to identify patients at a high risk for VTE. Each
risk factor is individually weighted according to a point-based scale.
– Active cancer (defined as presence of metastases or recent
chemotherapy), known thrombophilic condition, and reduced
patient mobility are each assigned a score of 3 points.
– Recent major surgery is assigned a score of 2 points.
– Advanced age (greater than 70 years), obesity (BMI greater than
30), bed rest, and hormone replacement therapy or oral
contraceptives are each assigned a score of 1 point.
Patients are identified as a high risk for VTE if they accumulate a sum
of 4 or more points. When the risk level is low, no medication is
recommended; when the risk level is high, a prophylactic strategy
using a high-dosage low-molecular-weight heparin is recommended.
II. The second part of the algorithm involved the exclusion criteria for
the use of VTE prophylaxis.
– Home anticoagulant therapy
– Contraindications to pharmacologic prophylaxis
– Active bleeding
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When feasible, the trial will be tailored to address the
specific needs emerging from the qualitative assessment.
We will collect feedbacks about usability, possible errors,
or inaccuracies of the information and recommendations
provided. We will offer the best possible solutions to cli-
nicians and hospital staff to overcome these problems.
We will further organize and facilitate group discussions
among participants to address negative perceptions or
misleading beliefs about CDSSs. The qualitative study
seeks to support the use of CDSS by participants, thus
increasing the integrity of the intervention and associ-
ated compliance.
Study outcomes
Primary outcome: the rate at which the medical prob-
lems, which are detected by the MediDSS software and
reported through the reminders, are resolved (i.e., reso-
lution rates).
Secondary outcomes: (i) resolution rates for the VTE
prevention reminders, (ii) in-hospital all causes mortality
(iii) VTE-related mortality, (iv) in-hospital morbidity for
VTE-related causes, and (v) the length of hospital stay
during the study period.
Sample size
We calculated the sample size on the basis of the pri-
mary outcome. A previous systematic review assessing
the effects of computer reminders delivered to clinicians
at the point-of-care on healthcare processes and out-
comes found a median improvement of 4.2 % in process
adherence across all reported process outcomes [57].
Accordingly, assuming resolution rates of 5 % in the
intervention group versus 3 % in the control group due
to a possible group contamination, we calculated that a
sample of 4230 reminders will be necessary to detect the
difference between the two groups (power = 0.90; α = 0.05,
two-sided; 1:1 allocation). Because estimates for intraclus-
ter correlation are not available, we increased the required
sample size (by 10 %) to 4650 reminders to account for
clustering by patient.
Moreover, based on a prior study evaluating EBMeDS,
which recorded an average of 0.30 reminders per individ-
uals triggered at baseline [58], we determined that a total
number of 15,500 patients (7750 per group) need to be
enrolled. This figure corresponds to a conservative esti-
mate of the recruitment period of 24 months for the in-
ternal medicine departments of the Vimercate Hospital.
Allocation and blinding
Anonymous patient identification (ID) numbers in the
EHR system will be the unit of randomization. An indi-
vidual external to the study group will generate the an-
onymous IDs using a formula based on patients’ unique
fiscal code numbers.
We will randomly assign patients to either the control
or experimental group with a 1:1 allocation. We will fol-
low a computer-generated randomization schedule strati-
fied by gender and age (0–30, 31–60, 61–80, >80 years)
using permuted blocks of random sizes [59]. Patients will
be randomized immediately after the first launch of their
EHR (entry of demographic data by physicians at hospital
admission), and the allocation will be maintained through
successive admissions.
Patients and study investigators (i.e., researchers, stat-
isticians, information technology specialists, and hospital
representatives) will be blinded to the allocation of par-
ticipants. We will maintain the blinding up to the data-
set disclosure. On the other hand, blinding of physicians
is not feasible due to the nature of the intervention: the
physician will know that a patient has been allocated to
the intervention group if an automatic, patient-specific
reminder is displayed on the screen.
Data collection
The data collection for this study will follow the stand-
ard data collection procedures of the AODV. We will
collect demographic (i.e., gender, age) and administrative
(i.e., anonymous patient ID, admission and discharge
dates, diagnoses) data from the EHR archive on a daily
basis. Information on reminders, including all scripts
that have been activated in a patient’s record, will also
be collected daily, but during the night, so as not to dis-
turb or slow down the use of the patient EHR.
Statistical methods
For the primary outcome (i.e., resolution rates), the re-
minder will serve as the unit of analysis, and the patient
the clustering factor. The patient will be the unit of ana-
lysis for the secondary outcomes (i.e., length of stay and
in-hospital mortality). All analyses will follow the
intention-to-treat principle: patients will be analyzed in
the group to which they have been randomized. Descrip-
tive statistics will be presented as means ± standard devi-
ations (SD), medians and interquartile ranges (IQR), or
percentages when appropriate. We will compare con-
tinuous variables using the Student’s t test when nor-
mally distributed, and the non-parametric two-sample
Wilcoxon rank-sum (Mann-Whitney) test when they are
not normally distributed. We will compare categorical
variables using the chi-squared test or the Fisher’s exact
test, as appropriate. To model the resolution rates of the
reminders, we will run a random effects logistic regres-
sion analysis, accounting for clustering by patient [60].
For hypothesis testing, we will consider a probability
level of less than 0.05 as statistically significant. All statis-
tical tests will be two-sided. We will use the Stata software
to perform all statistical analyses (Stata Corp., College
Station, TX, USA).
Moja et al. Implementation Science  (2016) 11:89 Page 6 of 10
Data monitoring
Data monitoring will inform the CODES trial conduct,
identifying the potential need for adjustments:
(i) Sample size recalculation: Because the sample size
calculation utilizes several assumptions, we will
analyze the first batch of data collected and adjust
the estimated sample size, if necessary, at the end of
the sequential roll-out of the intervention. The
24-month recruitment period may also be adjusted,
accordingly.
(ii) Interim analysis: We will perform an interim
analysis on the primary endpoint after 50 % of the
patients have been randomized, after 50 % of the
expected events have occurred, or after 12 months
of the study’s initiation (the assumed half-life of the
trial), whichever occurs first. An independent
statistician that is blind to the patient allocation will
perform the analysis. This analysis will inform
whether the intervention has been proven for efficacy
(beyond reasonable doubt). We will subsequently
decide whether (or not) it is necessary to modify the
study or prematurely terminate it, if necessary.
(iii)End of trial: The end of trial will occur 30 days after
the randomization of the last EHR. We will submit
an end of trial notification and final report to the
competent ethical committee, the AODV, and to the
sponsor.
Harms
We do not anticipate any harms (or other unintended
effects) to study participants. Intervention and control
groups will differ in the presence (intervention) or ab-
sence (control) of automatic reminders displayed on
physicians’ monitors. Patients assigned to the control
group will receive usual care without the reminders.
Nevertheless, we will consult an external advisory board
in the event that the discontinuation of the study be-
comes an option due to unforeseeable reasons.
Ethical and regulatory considerations
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki (October 2013) [61].
As the CODES trial has a cluster design (several re-
minders, the unit of analysis, may derive from the same
EHR, the unit of randomization), we followed the
Ottawa statement to identify research participants and
apply ethical and regulatory protections [62, 63]. The
intervention (electronic CDSS reminders) does not dir-
ectly target patients but physicians who can be consid-
ered as the participants of the study. The risks
associated with the participation of physicians in the
CODES trial are negligible. Physicians will be fully in-
formed about the involvement of the AODV in the
CODES trial and trained to use the intervention. Requir-
ing the signed consent of each physician is not feasible
and will impact on the validity and generalizability of
study results. Some have argued that healthcare profes-
sionals have an obligation to participate in health system
or knowledge translation research [64, 65]. We consider
that the waiver of signed consents will not adversely
affect the rights or welfare of the research participants.
Protocol amendments
Any changes to the research protocol that may impact
the study conduct (e.g., changes in study design, eligibil-
ity criteria, study outcomes, sample size, study proce-
dures, or significant administrative aspects) will require
a formal amendment of the protocol. We will communi-
cate any such amendments to the trial registry (Clinical-
Trials.gov) and notify the health authorities in accordance
with the Italian regulations. We will further seek the ap-
proval of the Ethical Committee for any amendments to
the protocol.
Confidentiality
The trial staff will ensure the maintenance of partici-
pants’ anonymity. The participants will be identified only
by their initials and anonymous patient ID number.
Depersonalized data will be extracted from the EHR. All
documents will be stored securely and accessible only by
the trial investigators and authorized personnel.
Clinical data collected during the study will only be ac-
cessible to the staff at AODV, thus complying with the
current medical practice of the hospitals. The trial inves-
tigators external to the hospitals (statistician, data man-
ager, information technology personnel, etc.) will not
have access to any information at the patients’ level.
The CODES trial will comply with the Italian Data
Protection Act, which requires data to be anonymized as
soon as it is practical to do so.
Dissemination policy
The trial results will be posted on ClinicalTrials.gov as
well as published in an open-access medical journal.
We will further disseminate the study results to the
health professionals of AODV who are involved in the
study.
Discussion
Strengths and limitations
The CODES trial has several strengths. First, the random-
ized controlled study design is recognized as the “gold
standard” for testing intervention outcome hypotheses,
allowing us to maximize the likelihood that the differences
observed between groups are due to the intervention ra-
ther than potential confounding factors. Second, the prag-
matic design of the study under conditions that mimics
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the actual use of CDSSs in practice increases the
generalizability of the results as well as allows a more
accurate estimation of the intervention’s true effective-
ness. Third, the choice of an intention-to-treat analysis
helps to ensure the pragmatic design of the study; in
other words, although not all physicians may adhere to
the reminders within the study, we anticipate that the
lack of compliance with evidence-based recommenda-
tions occurs in everyday practice.
We must note the methodological limitation that physi-
cians will not be blinded to the treatment allocation. When
a patient-specific reminder is automatically displayed on
the monitors, the physician will know that the particular
patient belongs to the intervention group. We are aware
that the unit of allocation (i.e., patient) and the lack of
physician blinding can lead to possible group contamin-
ation as one physician can have both intervention and
control group patients; in this case, a physician may apply
the knowledge from a reminder generated for an interven-
tion group patient to a control group patient. This possible
learning effect (contamination of knowledge) can decrease
the trial effect and lead to a more conservative effect esti-
mate (i.e., towards the null). Randomization at the phys-
ician level, however, does not eliminate the possibility of
contamination as physicians can care for patients across
different wards; this level of randomization would, more-
over, increase the organizational complexity of the study.
Conclusion
The use of CDSSs in healthcare systems is likely to in-
crease in the near future due to (i) growing concerns
about the quality of medical care; (ii) continuous calls
for a meaningful use of health information technology;
and (iii) increasing use of and familiarity with advanced
technology among new generations of physicians.
Through our pragmatic trial, we will contribute to the
current research and understanding of the effectiveness
of CDSSs in primary care and hospital settings. The re-
sults of our study may inform future research and
healthcare policy questions related to the feasibility and
value of CDSS use in healthcare systems.
Trial status
The implementation phase of the study was completed
in November 2015, when the CDSS (MediDSS) was fully
integrated with the hospital’s EHR (Tabula Clinica). Sub-
ject recruitment and data collection began in December
2015 in the Vimercate Hospital.
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